Metastatic Tumors Flashcards

1
Q

The most common malignant tumors of the liver

A

are metastatic lesions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Metastatic adenocarcinoma to the liver of unknown primary ? you should think of what?

A
  • often a primary IHC,

> > and this diagnosis must always be kept in mind

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Colorectal Metastases

A

Up to 60% Develop it through their life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

synchronously vs metachronously

A

synchronously&raquo_space;
at the time of diagnosis of primary disease

metachronously&raquo_space;
arbitrarily defined as >1 year after the diagnosis of primary disease

Literature suggests that synchronous liver metastases portend to a worse prognosis than metachronous disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

poor prognostic sign

A
  • pain
  • ascites
  • jaundice
  • weight loss
  • palpable mass
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What should you look for when observing Patient with Colon Cancer ?

A
  • rising CEA level on serial examinations
  • new solid mass on imaging studies are diagnostic of metastatic disease.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What most commonly in labs can be elevated also ?

A

ALP
GGT
lactate dehydrogenase.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what type of imaging requested ?

A
  • high-quality CT or MRI
  • thin-cut (5 mm)
  • high-resolution, dynamic, contrast-enhanced helical scanning techniques.
  • Timing with IV administration of a contrast agent should correspond to the portal venous phase to maximize hepatic parenchymal enhancement, which improves the disparity between parenchyma and tumor.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Workup for colorectal liver metastases

A
  • Colonoscopy > if it has been longer than 1 year since the last examination
  • CT abdominal and pelvic
  • CT Chest
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Do you need PET/CT ??

A
  • use of PET/CT did not result in significant changes in surgical management, and there was no difference in resectability or long-term outcomes between the two groups.
  • This trial provides definitive evidence that routine use of PET does not significantly affect outcomes among patients with potentially resectable colorectal cancer liver metastasis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What Chemotherapy regiment to consider for Advanced Disease ?

A
  • 5-FU with irinotecan or oxaliplatin combined
    with targeted antiangiogenic antibodies such as bevacizumab (antivascular endothelial growth factor antibody)
    or cetuximab (antiepidermal growth factor antibody)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Survival for Colorectal Liver Mets after Surgery ?

A

50 % survive 3 Yrs
20 % Survive 5 Yrs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what is the Problem with pre-op Chemo ?

A
  • associated with hepatic toxicity
    (steatohepatitis and sinusoidal obstructive syndrome)
    and higher rates of postoperative liver failure.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the poor prognostic factors?

A

poor prognostic factors include :
- extrahepatic metastases
- involved lymph nodes with the primary colorectal tumor
- synchronous presentation (or shorter disease-free interval)
- larger number of tumors
- bilobar involvement
- CEA level elevation more than 200 ng/mL
- size of largest hepatic tumor more than 5 cm
- involved histologic margins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

five preoperative factors as the most influential on outcome:

A

1- size larger than 5 cm
2- disease-free interval less than 1 year
3- more than one tumor
4- lymph node–positive primary
5- CEA level higher than 200 ng/mL.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Contraindication for Hepatectomy

A
  • the inability to resect all disease.
17
Q

what margin you aim for ? and locations for best outcomes ?

A
  • Wide margins more than 1 cm are appropriate
  • Sites associated with the best outcomes:

limited lung metastases
locoregional recurrences of the primary tumor
portal lymph nodes

18
Q

Recurrence rate after Tx ?

A
  • Overall, approximately 75% of patients have recurrence
  • in high-risk situations (e.g., four or more tumors, extrahepatic disease), recurrence rates approach 100%
19
Q

how do you approach recurrence ?

A
  • 50% of recurrences are isolated to the liver
  • ∼5% of all patients undergoing liver resection are candidates for a second liver resection.
  • second liver resection with complete removal of all disease can expect further 5-year survival rates of 30% to 40%.
  • Limited and isolated lung recurrences can also be resected with the potential for further long-term survival
20
Q

Adjuvant Therapy role ?

A

Adjuvant chemotherapy was independently associated with both progression-free survival and overall survival in multivariable analysis

21
Q

In summary for The role of Colorectal Liver Mets ?

A
  • level 1 clinical evidence that adjuvant systemic chemotherapy, when combined with liver resection, modestly improves progression-free survival in patients with colorectal liver metastases.
  • At this time, the general consensus is that patients with liver metastases benefit from 6 months of perioperative adjuvant therapy.
22
Q

Neoadjuvant chemotherapy role ?

A

Neoadjuvant chemotherapy for resectable metastases is also a common strategy to treat occult systemic disease and can be helpful in selecting the small group of patients (<10%) who progress while receiving chemotherapy and have a poor outcome after hepatectomy.

23
Q

Rationale of Using HAI ?

A

The rationale for adjuvant hepatic artery chemotherapy is based on the fact that liver metastases derive most of their blood supply from the hepatic artery.

Regional infusion of chemotherapeutic agents such as fluorodeoxyuridine has hepatic extraction rates of 90%, providing high local concentrations with minimal systemic toxicity

HAI therapy with fluorodeoxyuridine to be more effective than hepatectomy alone, with significantly improved disease-free survival

24
Q

Unresectable liver-only metastatic disease

A

preoperative systemic and HAI chemotherapy has been shown to convert some patients to resection candidates.

25
Q

Strategies to extend the limits of liver resection

A
  • parenchyma-preserving segmental resections
  • two-stage operations
  • thermal ablative techniques, such as cryoablation or RFA
  • microwave ablation is being studied as a treatment for these patients,
26
Q

Recurrence rate increase with what ?

A
  • recurrence rates increase with the size of the tumor and when ablation is performed for the tumor close to the vessels.
  • microwave ablation either alone or in combination with liver resection can provide good long-term results.
  • multiple bilobar tumors can be extirpated by a combination of resection and ablation with preservation of sufficient hepatic parenchyma.
27
Q

Neuroendocrine Metastases to live

A

gastrinomas
glucagonomas
somatostatinomas
nonfunctional neuroendocrine tumors.

Insulinomas and carcinoid tumors metastasize to the liver less commonly.

28
Q

Tx options ?

A
  • Long-acting somatostatin analogues
    » alleviating hormonal symptoms
    » cytostatic role as well
  • Hepatic arterial embolization or thermo ablative
    » cytoreducing tumor loads
    » alleviating symptoms of hormonal excess.
  • Liver Resection
    » enucleation and wedge resection are reasonable options.
29
Q

Noncolorectal, Nonneuroendocrine Metastases

A

Patients with liver-only metastatic disease should be treated with systemic chemotherapy before being considered for liver resection

30
Q

Which Liver Mets has the best Prognosis from all the others in this category ?

A
  • long-term survival after resection of isolated liver metastases from upper gastrointestinal tumor, in general, these patients have a dismal prognosis and liver resection is not recommended.
  • In most series, liver resection for genitourinary tumors has the best prognosis, and in well-selected patients, liver resection should be considered.